Compare TOWN & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOWN | PTGX |
|---|---|---|
| Founded | 1998 | 2006 |
| Country | United States | United States |
| Employees | 1939 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 9.3B |
| IPO Year | N/A | 2016 |
| Metric | TOWN | PTGX |
|---|---|---|
| Price | $37.41 | $148.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $108.23 |
| AVG Volume (30 Days) | ★ 480.4K | 442.7K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.09% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.35 |
| Revenue | N/A | N/A |
| Revenue This Year | $35.63 | $874.25 |
| Revenue Next Year | $5.18 | N/A |
| P/E Ratio | ★ $16.23 | $62.16 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.91 | $57.90 |
| 52 Week High | $39.03 | $160.81 |
| Indicator | TOWN | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 51.61 | 53.59 |
| Support Level | $36.98 | $127.98 |
| Resistance Level | $38.01 | $160.81 |
| Average True Range (ATR) | 0.51 | 5.71 |
| MACD | -0.10 | -1.51 |
| Stochastic Oscillator | 61.04 | 35.40 |
Towne Bank is a financial services company serving individuals, commercial enterprises and professionals, offering retail and commercial banking services in Virginia and North Carolina. The company has four reportable segments: Banking, which provides loan and deposit services, commercial mortgage brokerage, and investment and asset management services; Mortgage, which originates mortgage loans principally sold in the secondary market through purchase commitments from investors; Resort Vacation Management, which provides residential resort property management services; and Insurance, which provides property, casualty, life and health insurance solutions for businesses, individuals and community organizations through a variety of carriers.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.